Latest posts tagged with #HSCT on Bluesky
Unmanipulated bone marrow infusion without conditioning can rescue RECQL4-/- severe combined immunodeficiency. New study from Alexandra Grier and colleagues @chopresearch.bsky.social: rupress.org/jhi/article/...
#ClinicalPhenotypes #immunodeficiencies #InbornErrorsOfImmunity #SCID #HSCT
Hematopoietic stem cell transplantation following invasive mold infection in chronic granulomatous disease: insights from a case series and literature review. New study from Hugo Bes-Berlandier, Fanny Lanternier @hopitalnecker.bsky.social and colleagues: rupress.org/jhi/article/...
#CGD #HSCT
IPOPI was pleased to take part in the PID Symposium organised by the VIVA Foundation for Children with Cancer in Singapore.
Strengthening collaboration across disciplines remains essential to improve outcomes for people living with primary immunodeficiencies.
#PID #HSCT #RareDiseases #GlobalHealth
Bes-Berlandier, Lanternier et al @hopitalnecker.bsky.social describe the characteristics & clinical outcomes of chronic granulomatosis disease patients undergoing hematopoietic stem cell transplantation within 2 years after an invasive mold infection diagnosis rupress.org/jhi/article/...
#CGD #HSCT
🩸Brazilian pediatric consensus reviews 3 post-allogeneic #HSCT cell therapies: DLI to amplify GvL, stem cell boost for graft dysfunction, and MSC for refractory #GvHD. 🆓https://doi.org/10.46765/2675-374X.2025v6n1e309
#MedSky #hematology #oncology #oncopediatrics #JBMTCT
Hematopoietic stem cell transplant with a carrier donor rescues CD40L deficiency. New case report from Christen L. Ebens @umnpeds.bsky.social, Amir A. Sadighi Akha @mayoclinic.org and colleagues: rupress.org/jhi/article/...
#InbornErrorsOfImmunity #Therapeutics #HSCT
Lyytikäinen, Johansson et al. report two novel assays to characterize T cell function in two patients with DCLRE1C variants diagnosed with leaky severe combined immunodeficiencies (#SCID). rupress.org/jhi/article/...
#SCID #PrimaryImmunodeficiency #InbornErrorsOfImmunity #HSCT #ClinicalImmunology
@jhumimmunity.org: Ebens et al demonstrate successful allogeneic #HSCT of CD40L deficiency using an asymptomatic carrier mother donor w/ achievement of 32% CD40L expression, recovery of thymopoiesis, normal T cell diversity & functional outcomes of T & B cell interactions rupress.org/jhi/article/...
Ebens, Akha et al. demonstrate successful allogeneic #HSCT of CD40L deficiency using an asymptomatic carrier mother donor, with achievement of 32% CD40L expression, recovery of thymopoiesis, normal T cell diversity and functional outcomes of T and B cell interactions. rupress.org/jhi/article/...
Beyond survival: Multisystem long-term outcomes following #HSCT in chronic granulomatous disease. New study from Valentina Guarnieri, Reem Elfeky and colleagues @greatormondst.bsky.social: rupress.org/jhi/article/...
#InbornErrorsOfImmunity #immunodeficiencies #CGD
@esidsociety.bsky.social
In @jhumimmunity.org, Guarnieri, Elfeky et al. @greatormondst.bsky.social report long-term outcomes after #HSCT in children with chronic granulomatous disease. While survival is excellent, a wide range of autoimmune and organ-specific late effects emerge. rupress.org/jhi/article/...
#CGD
Guarnieri, Elfeky et al. @greatormondst.bsky.social report long-term outcomes after #HSCT in children with chronic granulomatous disease. While survival is excellent, a wide range of autoimmune and organ-specific late effects emerge. rupress.org/jhi/article/...
#CGD #InbornErrorsOfImmunity
Pediatric Acute Myeloid Leukemia: timing is critical.
The 2025 Brazilian consensus shows that any detectable MRD after HSCT predicts relapse and poor survival. Early, serial MRD monitoring is decisive, and delays can cost a cure.
doi.org/10.46765/267...
#HSCT #HemeOnc #HemeSky #MedSky #JBMTCT
HSCT yields satisfactory long-term outcomes in patients with PNP deficiency. OS was best in early-diagnosed patients without neurologic symptoms. Read in Blood: buff.ly/MhfvvBD #HSCT #BloodJournal
Fred Hutch is recruiting a full-time Associate Professor in the Translational Science & Therapeutics Division. We are seeking candidates with expertise in hematopathology and molecular pathology, and interest in #HSCT, #IMTX and lymphoid neoplasms. Apply: https://apply.interfolio.com/178338
Pleased to announce FDA approval of YARTEMLEA® (narsoplimab-wuug). First and only approved lectin pathway inhibitor therapy indicated for TA-TMA.
More info: bit.ly/497VHeF
#YARTEMLEA #narsoplimab #ComplementInhibition #RareDisease #TMAtreatment #NowApproved #MASP2inhibitor #tma #hsct #omeros #FDA
🩸This study shows that hematopoietic cell transplantation is curative for >150 inborn errors of immunity. In Wiskott–Aldrich syndrome, early transplant achieves ~91% 5-year survival, especially with robust donor myeloid chimerism.
doi.org/10.46765/267...
#HSCT #HemeOnc #HemeSky #MedSky #JBMTCT
Fred Hutch is recruiting a full-time Associate Professor in the Translational Science & Therapeutics Division. We are seeking candidates with expertise in hematopathology and molecular pathology, and interest in #HSCT, #IMTX and lymphoid neoplasms. Apply: https://apply.interfolio.com/178338
Fred Hutch is recruiting a full-time Associate Professor in the Translational Science & Therapeutics Division. We are seeking candidates with expertise in hematopathology and molecular pathology, and interest in #HSCT, #IMTX and lymphoid neoplasms. Apply: https://apply.interfolio.com/178338
💊FDA Approval | #Omisirge
First cellular therapy for severe aplastic anemia (#SAA) — Omisirge (omidubicel-onlv), the first #HSCT option for patients without a compatible donor. Restores blood & immune system.Faster recovery.Orphan Drug & Priority Review
🔗https://ow.ly/1PhU50XG3OJ
La #FDA 🇺🇸 a approuvé la 1ère thérapie de greffe de cellules souches hématopoïétiques ( #HSCT) pour traiter les patients atteints d’#Anémie aplasique sévère ( #SAA).
www.fda.gov/news-events/...
Congrats to Fred Hutch #HSCT pioneer Dr. Rainer Storb on receiving the Wallace H. Coulter Award for Lifetime Achievement in Hematology at #ASH25! 🩸 👉 bit.ly/3MkdPdx
Fred Hutch at #ASH25: Don't miss #HSCT pioneer Dr. Rainer Storb receive the Wallace H. Coulter Award for Lifetime Achievement in Hematology! 🩸 👉 https://bit.ly/3MkdPdx
Great event at the XIX Course on Infections in Immunocompromised Patients – HCFMUSP!
I had the opportunity to give an update on CMV in the context of HSCT #HSCT #BMT #IDSky #TxID
🔥 off the press. Great work by Dr Brennan Collis @Austin_Health @dukehealth.bsky.social @thetxidjournal.bsky.social #TID #HSCT #CMV
onlinelibrary.wiley.com/doi/10.1111/...
And reporting negative or unexpected results is just as essential as sharing success stories — it’s how our field continues to evolve.
#PrimaryImmunodeficiency #Immunology #HSCT #RareDiseases
🧬 Today’s question focuses on how #Lyfgenia differs from allogeneic #HSCT.
See the answer and explanation on the next slide!
@asgct.bsky.social @ash.edu.hematology.org @bsochaem.bsky.social @dukemedschool.bsky.social @dgsomucla.bsky.social @harvardmed.bsky.social @bcmhouston.bsky.social
The newest @astct.bsky.social guidelines for #CMV in #HSCT and #CAR-T were published in "Transplantation and Cellular Therapy" this year.
@txidfellows.bsky.social ✅out this table of treatment options based on genotype!
Find this and other guidelines at
transplantid.net?guidelines=R...
“Year 5” https://youtu.be/oBidOS-u630?si=WzedlbBDvSTg9ejm
5 years ago, at 12:09 PM, I received my stem cells. I still struggle every day. Am WAY better though. The alternative would’ve been… dire.
I’ll never have to ask:
“What if…”
#HSCT #ms #multipleSclerosis #stemCells
🚨 Preliminary results! 🚨 Our systematic review & meta-analysis on stopping quinolone prophylaxis pre-engraftment in HSCT — just presented at the XXIV Brazilian Congress of Infectious Diseases.
#HSCT 🧬
#InfectiousDiseases 🌍 #BMT 💉 #IDSky 🌌 #TxID
